

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Monday, September 18, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L8	(process\$5 or degrad\$5 or synthes\$5) same L6	11
<input type="checkbox"/>	L7	carbohydrate same L6	0
<input type="checkbox"/>	L6	(mutant or variant or modif\$5) same L5	35
<input type="checkbox"/>	L5	(gene or sequence or polynucleotide) same L4	379
<input type="checkbox"/>	L4	(glycosyl adj hydrolase)	626
<input type="checkbox"/>	L3	beta and L2	28
<input type="checkbox"/>	L2	glycosidase and L1	38
<input type="checkbox"/>	L1	davis.in.	43791

END OF SEARCH HISTORY

STN SEARCH

10/679,692

9/15/2006

=> index bioscience medicine

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:26:20 ON 18 SEP 2006

71 FILES IN THE FILE LIST IN STNINDEX

=> S (glycosyl (w) hydrolase)

70 FILE AGRICOLA
1 FILE AQUALINE
11 FILE AQUASCI
85 FILE BIOENG
417 FILE BIOSIS
114 FILE BIOTECHABS
114 FILE BIOTECHDS
177 FILE BIOTECHNO
98 FILE CABA
458 FILE CAPLUS
14 FILE CEABA-VTB
4 FILE CONFSCI
1 FILE CROPU
4 FILE DDFB
1 FILE DDFU
848 FILE DGENE
19 FILE DISSABS
4 FILE DRUGB
1 FILE DRUGU
4 FILE EMBAL
247 FILE EMBASE
339 FILE ESBIODASE
10 FILE FROSTI
105 FILE FSTA
1517 FILE GENBANK
32 FILE IFIPAT
35 FILE JICST-EPLUS
258 FILE LIFESCI
43 FILES SEARCHED...
294 FILE MEDLINE
4 FILE OCEAN
122 FILE PASCAL
416 FILE SCISEARCH
87 FILE TOXCENTER
269 FILE USPATFULL
51 FILE USPAT2
1 FILE VETB
1 FILE WATER
39 FILE WPIDS
39 FILE WPINDEX
1 FILE NLDB

40 FILES HAVE ONE OR MORE ANSWERS, 71 FILES SEARCHED IN STNINDEX

L2 QUE (GLYCOSYL (W) HYDROLASE)

-> d rank

F1 1517 GENBANK
F2 848 DGENE
F3 458 CAPLUS
F4 417 BIOSIS
F5 416 SCISEARCH
F6 339 ESBIODASE
F7 294 MEDLINE
F8 269 USPATFULL
F9 258 LIFESCI
F10 247 EMBASE

F11 177 BIOTECHNO
F12 122 PASCAL
F13 114 BIOTECHABS
F14 114 BIOTECHDS
F15 105 FSTA
F16 98 CABA
F17 87 TOXCENTER
F18 85 BIOENG
F19 70 AGRICOLA
F20 51 USPAT2
F21 39 WPIDS
F22 39 WPINDEX
F23 35 JICST-EPLUS
F24 32 IFIPAT
F25 19 DISSABS
F26 14 CEABA-VTB
F27 11 AQUASCI
F28 10 FROSTI
F29 4 CONFSCI
F30 4 DDFB
F31 4 DRUGB
F32 4 EMBAL
F33 4 OCEAN
F34 1 AQUALINE
F35 1 CROPU
F36 1 DDFU
F37 1 DRUGU
F38 1 VETB
F39 1 WATER
F40 1 NLDB

=> file f3-f15

FILE 'CAPLUS' ENTERED AT 12:28:30 ON 18 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:28:30 ON 18 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 12:28:30 ON 18 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'ESBIOBASE' ENTERED AT 12:28:30 ON 18 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:28:30 ON 18 SEP 2006

FILE 'USPATFULL' ENTERED AT 12:28:30 ON 18 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 12:28:30 ON 18 SEP 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:28:30 ON 18 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 12:28:30 ON 18 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PASCAL' ENTERED AT 12:28:30 ON 18 SEP 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:28:30 ON 18 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 12:28:30 ON 18 SEP 2006
COPYRIGHT (C) 2006 International Food Information Service

=> s L2
L3 3216 L2

=> S (gene or sequence or polynucleotide)(s)L3
9 FILES SEARCHED...
L4 1563 (GENE OR SEQUENCE OR POLYNUCLEOTIDE)(S) L3

=> S (mutant or variant or modif?)(s) L4
L5 105 (MUTANT OR VARIANT OR MODIF?)(S) L4

=> S (process? or degrad? or synthes?)(s)L5
10 FILES SEARCHED...
L6 38 (PROCESS? OR DEGRAD? OR SYNTHES?)(S) L5

=> S carbohydrat? (s)L6
L7 6 CARBOHYDRAT? (S) L6

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 6 DUP REM L7 (0 DUPLICATES REMOVED)

=> d ibib abs L8 1-6

L8 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2006:34176 USPATFULL <<LOGINID::20060918>>

TITLE: Novel full length cDNA

INVENTOR(S): Isogai, Takao, Ibaraki, JAPAN
Sugiyama, Tomoyasu, Tokyo, JAPAN
Otsuki, Tetsuji, Kisarazu-shi, JAPAN
Wakamatsu, Ai, Kisarazu-shi, JAPAN
Sato, Hiroyuki, Toyonaka-shi, JAPAN
Ishii, Shizuko, Kisarazu-shi, JAPAN
Yamamoto, Jun-ichi, Kisarazu-shi, JAPAN
Isono, Yuuko, Kisarazu-shi, JAPAN
Hio, Yuri, Kisarazu-shi, JAPAN
Otsuka, Kaoru, Honjo-shi, JAPAN
Nagai, Keiichi, Tokyo, JAPAN
Irie, Ryotaro, Kisarazu-shi, JAPAN
Tamechika, Ichiro, Hirakata-shi, JAPAN
Seki, Naohiko, Chiba-shi, JAPAN
Yoshikawa, Tsutomu, Kisarazu-shi, JAPAN
Otsuka, Motoyuki, Tokyo, JAPAN
Nagahari, Kenji, Tokyo, JAPAN
Masuho, Yasuhiko, Tokyo, JAPAN

PATENT ASSIGNEE(S): RESEARCH ASSOCIATION FOR BIOTECHNOLOGY (non-U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006029945 A1 20060209
APPLICATION INFO.: US 2005-72512 A1 20050307 (11)
RELATED APPLN. INFO.: Division of Ser. No. US 2002-104047, filed on 25 Mar
2002, GRANTED, Pat. No. US 6943241

NUMBER DATE

PRIORITY INFORMATION: JP 2001-379298 20011105
US 2002-350978P 20020125 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007, US

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 12974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel full-length cDNAs are provided. 1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2005:131264 USPATFULL <<LOGINID::20060918>>

TITLE: Secreted and transmembrane polypeptides and nucleic acids encoding the same

INVENTOR(S): Ashkenazi, Avi J., San Mateo, CA, UNITED STATES

Baker, Kevin P., Darnestown, MD, UNITED STATES

Botstein, David, Belmont, CA, UNITED STATES

Desnoyers, Luc, San Francisco, CA, UNITED STATES

Eaton, Dan L., San Rafael, CA, UNITED STATES

Ferrara, Napoleone, San Francisco, CA, UNITED STATES

Fong, Sherman, Alameda, CA, UNITED STATES

Gerber, Hanspeter, San Francisco, CA, UNITED STATES

Gerritsen, Mary E., San Mateo, CA, UNITED STATES

Goddard, Audrey, San Francisco, CA, UNITED STATES

Godowski, Paul J., Hillsborough, CA, UNITED STATES

Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES

Gurney, Austin L., Belmont, CA, UNITED STATES

Klavin, Ivar J., Lafayette, CA, UNITED STATES

Napier, Mary A., Hillsborough, CA, UNITED STATES

Pan, James, Belmont, CA, UNITED STATES

Paoni, Nicholas F., Belmont, CA, UNITED STATES

Roy, Margaret Ann, San Francisco, CA, UNITED STATES

Stewart, Timothy A., San Francisco, CA, UNITED STATES

Tumas, Daniel, Orinda, CA, UNITED STATES

Watanabe, Colin K., Moraga, CA, UNITED STATES

Williams, P. Mickey, Half Moon Bay, CA, UNITED STATES

Wood, William I., Hillsborough, CA, UNITED STATES

Zhang, Zemin, Foster City, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES
(U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005112725 A1 20050526

APPLICATION INFO.: US 2004-978255 A1 20041029 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-989862, filed on 19

Nov 2001, PENDING Continuation of Ser. No. US

2001-941992, filed on 28 Aug 2001, PENDING Continuation

of Ser. No. WO 2000-US8439, filed on 30 Mar 2000,

PENDING Continuation-in-part of Ser. No. US 380137,

ABANDONED A 371 of International Ser. No. WO

1999-US12252, filed on 2 Jun 1999

NUMBER DATE

PRIORITY INFORMATION: US 1999-141037P 19990623 (60)

US 1998-88810P 19980610 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD
ROAD, MENLO PARK, CO, 94025-3506, US

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1-118

NUMBER OF DRAWINGS: 330 Drawing Page(s)

LINE COUNT: 38226

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides and to nucleic

acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 6 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
ACCESSION NUMBER: 2005-21532 BIOTECHDS <<LOGINID::20060918>>

TITLE: Novel modified polypeptide with carbohydrate processing
enzymatic activity, including substitution of amino acid
residue forming catalytic nucleophile of active site, by less
nucleophilic residue, useful for hydrolyzing beta glycoside;
involving vector-mediated gene transfer and expression in
host cell for therapy

AUTHOR: DAVIS B G

PATENT ASSIGNEE: ISIS INNOVATION LTD

PATENT INFO: WO 2005059126 30 Jun 2005

APPLICATION INFO: WO 2004-GB5266 15 Dec 2004

PRIORITY INFO: GB 2003-29011 15 Dec 2003; GB 2003-29011 15 Dec 2003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2005-497551 [50]

AN 2005-21532 BIOTECHDS <<LOGINID::20060918>>

AB DERWENT ABSTRACT:

NOVELTY - A ***modified*** polypeptide (P1) having
carbohydrate ***processing*** enzymatic activity, and
comprising a ***modification*** that includes substitution of the
amino acid residue forming the catalytic nucleophile of an active site,
by a less nucleophilic amino acid residue, which retains some
nucleophilic activity, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following: (1) a ***polynucleotide*** (P2) encoding (P1); (2)
expression vector (V1) comprising (P2); and (3) host cell transformed
with (V1).

WIDER DISCLOSURE - The following are disclosed: (1) microarray
comprising (P2); and (2) non-human animals comprising (P2).

BIOTECHNOLOGY - Preferred Polypeptide: (P1) comprises amino acid
sequence chosen from (a) a fully defined 489 amino acid (SEQ ID

No. 2) ***sequence*** given in the specification, comprising a
substitution of an amino acid equivalent to an amino acid residue Glu at
position 387, by a less nucleophilic residue, (b) amino acid
sequence of family I ***glycosyl*** ***hydrolase***, that
comprises a substitution of an amino acid equivalent to an amino acid
residue Glu at position 387 of SEQ ID No. 2, by a less nucleophilic
residue, and (c) a ***variant*** of amino acid ***sequence*** of
(a) or (b) having ***carbohydrate*** ***processing*** enzymatic
activity and comprising a substitution at a position equivalent to Glu at
position 387 of SEQ ID No. 2 by a less nucleophilic residue, where the
less nucleophilic residue retains nucleophilic activity. The less
nucleophilic amino acid residue is chosen from tyrosine, asparagine,
cysteine, glutamine and arginine. (P1) has glycosyl synthase,

glycosyl ***hydrolase*** and/or transglycosylase activity.

The family I ***glycosyl*** ***hydrolase*** is *Sulfolobus*
solfataricus beta-glycosidase. (P1) further comprises one or more
mutations chosen to broaden the substrate specificity of the polypeptide
compared to a polypeptide not so ***modified***, where the mutations
are chosen from (a) at least one of W433, E432 and M439 of SEQ ID No. 2,
(b) at least one amino acid residue equivalent to W433, E432 and M439 of
SEQ ID No. 2 in the amino acid ***sequence*** of family I

glycosyl ***hydrolase***, and (c) at least one amino acid
mutation at a position equivalent to W433, E432 and M439 of SEQ ID No. 2
in a ***variant*** of (a) or (b) having ***carbohydrate***

processing enzymatic activity. (P1) comprises (a) SEQ ID No. 2
having one or more of amino acid residues such as Trp, Glu and Met at
position 433, 432 and 439, substituted by cysteine, valine and alanine;

(b) the amino acid ***sequence*** of family I ***glycosyl***
hydrolase, having at least one amino acid residue equivalent to

Trp, Glu and Met at position 433, 432 and 439 of SEQ ID No. 2, substituted by cysteine, valine and alanine; or (c) ***variant*** of (a) or (b) having at least one amino acid residue equivalent to Trp, Glu and Met at position 433, 432 and 439 of SEQ ID No. 2, substituted by cysteine, valine and alanine.

USE - (P1) is useful for hydrolyzing, ***synthesizing*** or transglycosylating beta glycoside, which involves contacting a glycoside substrate with (P1), where the glycoside substrate is chosen from glucoside, galactoside, fucoside, xyloside, mannoside and glucuronide. (P1) is contacted with a sample containing at least two different glycosides (claimed). (P1) is useful for generating glycoproteins, therapeutic molecules, and antibiotics in particular macrolide antibiotics. (P1) is useful in food industry to achieve depulping, in detergents, and in therapeutical applications. (P1) is useful in developing glycoconjugates for use in lectin enzyme activated prodrug system.

ADVANTAGE - (P1) has glycosyl synthase, ***glycosyl*** ***hydrolase*** and/or transglycosylase activity (claimed). (P1) is compatible at high temperature and in organic solvents, and forms glycosidic linkages between two monosaccharides, without the need for protection or activation steps, thus acting as super beta-catalyst. (I) can be produced in large-scale and is purified by HPLC techniques. (I) minimizes the hydrolysis of transglycosylation products and consequently improves transglycosylation yields, in comparison with wild-type glycosidase.

EXAMPLE - The ***gene*** (wild type, lac S) encoding the thermophilic, retaining, exo-beta-glycosidase, was isolated from *Sulfolobus solfataricus* MT-4 strain (SSbetaG). The wild type lac S, was then amplified by PCR using primers having sequences such as 5'-CCATGGGACACCACCACCACCACCACCTCATTAC-3' and 3'-CPCGAGTTAGTGCCCTTTATGGCTTTACTGGAGGTAC-5'. The PCR product was cloned into pCR2.1. Mutations were introduced into the lac S ***gene*** coding ***sequence*** (in pCR2.1) according to Stratagene QuickChange mutagenesis system. Mutated coding ***sequence*** were cloned into the NcoI/XhoI sites of expression vector pET-24-d(+), and transformed into *Escherichia coli* BL21 (DE3). Putative transformants were identified by colony PCR using SSbetaG coding ***sequence*** primers. Selected clones were grown in LB medium containing kanamycin (50 micrograms/ml) at 37degreesC to an optical density of 0.6 at 600 nm, and the target protein was induced by addition of 0.1 M isopropyl-beta-D-thiogalactopyranoside (IPTG). Then, the cells were obtained, lysed, and the ***modified*** glycosidase were purified using nickel-chelation chromatography. The 28 mg/L (95% purity) of E387Y SsbetaG ***mutant*** enzyme was obtained.(50 pages)

L8 ANSWER 4 OF 6 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
ACCESSION NUMBER: 2004-07676 BIOTECHDS <<LOGINID::20060918>>

TITLE: Novel mutant *Chrysosporium* strain comprising nucleic acid
sequence encoding polypeptide of interest such as proteases
and lipases, the nucleic acid sequence being operably linked
to expression-regulating region;
involving vector-mediated gene transfer and expression in
host cell

AUTHOR: EMALFARB M A; BURLINGAME R P; OLSON P T; SINITSYN A P;
PARRICHE M; BOUSSON J C; PYNNONEN C M; PUNT P J; VAN ZEIJL C
M J

PATENT ASSIGNEE: EMALFARB M A; BURLINGAME R P; OLSON P T; SINITSYN A P;
PARRICHE M; BOUSSON J C; PYNNONEN C M; PUNT P J; VAN ZEIJL C
M J

PATENT INFO: US 2004002136 1 Jan 2004

APPLICATION INFO: US 2003-394568 21 Mar 2003

PRIORITY INFO: US 2003-394568 21 Mar 2003; WO 1998-6496 6 Oct 1998

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2004-061663 [06]

AN 2004-07676 BIOTECHDS <<LOGINID::20060918>>

AB DERWENT ABSTRACT:

NOVELTY - A ***mutant*** *Chrysosporium* strain (I) comprising a
nucleic acid ***sequence*** encoding a polypeptide of interest, the
nucleic acid ***sequence*** being operably linked to an

expression-regulating region and optionally a secretion signal
sequence, the ***mutant*** strain expressing the polypeptide of interest at a higher level than the corresponding non- ***mutant*** strain under the same conditions, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a nucleic acid construct (II) comprising a nucleic acid expression-regulatory region derived from *C. lucknowense*, operably linked to a polypeptide-encoding nucleic acid ***sequence***; (2) a recombinant microorganism (III) containing (II), and capable of expressing the polypeptide encoded by the coding nucleic acid ***sequence***; (3) producing (M1) (I), involves stably introducing a nucleic acid ***sequence*** encoding a heterologous or homologous polypeptide into a *Chrysosporium* strain, the nucleic acid ***sequence*** being operably linked to an expression regulating region; (4) a protein (P1) corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 7, exhibiting at least 75% amino acid identity as determined by the BLAST algorithm with a fully defined ***sequence*** of 465 amino acids (S1) as given in specification, or its part having at least 20 contiguous amino acids which are identical to the corresponding part of the amino acid ***sequence*** 1-246 or 394-526 of (S1); (5) a protein (P2) corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 10, exhibiting at least 70% or 65% amino acid identity as determined by the BLAST algorithm with a fully defined ***sequence*** of 465 amino acids (S2), or its part having at least 20 contiguous amino acids which are identical to the corresponding part of the amino acid ***sequence*** 1-383 of (S2); (6) a protein corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 10 and comprising a cellulose-binding domain chosen from (a) domains having at least 75% amino acid identity with the amino acid ***sequence*** 22-53, and (b) domains having at least 20 contiguous amino acids identical to a part of amino acid ***sequence*** 22-53 of (S2); (7) a fungal ***glycosyl*** ***hydrolase*** of family 10, comprising a cellulose-binding domain, not derived from *Fusarium oxysporum*; (8) a protein (P3) corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 12; (9) a protein (P4) corresponding to a *Chrysosporium* glyceraldehyde phosphate dehydrogenase; (10) a protein (P5) corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 45; (11) a protein (P6) corresponding to a *Chrysosporium* ***glycosyl*** ***hydrolase*** family 6; (11) a nucleic acid ***sequence*** (IV) encoding any one of the proteins from (P1)-(P6); (12) a nucleic acid ***sequence*** comprising at least 70% of the nucleotides contained in the 5'-noncoding region of a nucleic acid ***sequence*** (NA) chosen from tccaaccctaaagctgatatcac, cctggatagctctgtccattc, ttatttttccaggtaccagcatgcc and a fully defined ***sequence*** of 1570 nucleotides or 74 nucleotides as given in specification; (13) a nucleic acid construct (V) comprising a nucleic acid expression-regulatory region derived from *Chrysosporium*, contained in the 5'-noncoding region of (NA), operationally linked to a nucleic acid ***sequence*** encoding a polypeptide of interest; (14) a recombinant microbial strain (VI) containing (V), and capable of expressing the polypeptide encoded by the coding nucleic acid ***sequence***; (15) a recombinant microbial strain (VII) containing (IV), and capable of expressing the polypeptide encoded by the coding nucleic acid ***sequence***; and (16) an oligonucleotide probe (VIII) comprising at least 15 contiguous nucleotides of the (NA), or its complement.

BIOTECHNOLOGY - Preferred ***Mutant***: (I) is obtained by recombinant methods which involves stable introduction of at least one heterologous nucleic acid ***sequence*** chosen from heterologous polypeptide-encoding nucleic acid sequences, heterologous signal sequences and heterologous expression-regulating sequences. The polypeptide of interest is a heterologous polypeptide of plant, animal (including human), insect, algal, bacterial, archaeobacterial or fungal origin. The polypeptide of interest is a homologous polypeptide which is expressed at a higher level than in the corresponding non- ***mutant*** strain under the same conditions. The polypeptide of interest is chosen from ***carbohydrate*** - ***degrading*** enzymes, proteases, lipases, esterases, other hydrolases, oxidoreductases and transferases. The polypeptide of interest is chosen from fungal enzymes allowing

(over)production of primary metabolites, including organic acids, and secondary metabolites, including antibiotics. The polypeptide of interest is inactivated at a pH below 6. The polypeptide of interest exhibits optimal activity and/or stability at a pH above 6, and/or has more than 70% of its activity and/or stability at a pH above 6. (I) comprises a heterologous signal *****sequence*****. (I) comprises a fungal signal *****sequence*****. The fungal signal *****sequence***** is a signal *****sequence***** of a cellulase, beta-galactosidase, xylanase, pectinase, esterase, protease, amylase, polygalacturonase or hydrophobin. (I) further comprises a selectable marker. The selectable marker confers resistance to a drug or relieves a nutritional defect. (I) comprises a heterologous/fungal expression-regulating region. The expression-regulating region comprises an inducible promoter or high expression promoter. (I) is obtained by mutagenesis steps, the steps including at least one step chosen from UV irradiation and chemical mutagenesis. The mutagenesis steps comprise a first UV irradiation step, a N-methyl-N'-nitro-N-nitrosoguanidine treatment step, and a second UV irradiation step. (I) is derived from *Chrysosporium lucknowense*. The *****mutant***** is derived from a *C. lucknowense* *****mutant***** strain chosen from *C. lucknowense* strain C1 (VKM F-3500 D), UV13-6 (VKM F-3632 D), NG7C-19 (VKM F-3633 D), and UV18-25 (VKM F-3631 D). When a *Trichoderma reesei* strain and the *C. lucknowense* strain are cultured under equivalent optimal conditions, when the *Trichoderma* culture strains a viscosity of 200-600 cP, the *Chrysosporium* strain exhibits a biomass of less than half that of the *Trichoderma*. The strain producing at least the amount of cellulase in moles per liter as produced by any of the *C. lucknowense* *****mutant***** strains C1 (VKM F-3500 D), UV13-6 (VKM F-3632 D), NG7C-19 (VKM F-3633 D), and UV18-25 (VKM F-3631 D). The strain produces less protease than produced by the *C. lucknowense* strain C1 (VKM F-3500 D). The strain produces less than half the amount of protease produced by the C1 strain. Preferred Construct: In (II), the expression-regulatory region is derived from a *C. lucknowense* strain chosen from C1 (VKM F-3500 D) and UV18-25 (VKM F-3631 D). The expression-regulatory region comprises a promoter *****sequence***** associated with cellulase expression, xylanase expression, or *gpdA* expression. Preferred Microorganism: (III) is a fungal strain. Preferred Method: In (M1), the nucleic acid is introduced by the protoplast transformation method. Preferred Probe: (VIII) is 20-50 nucleotides in length and is labeled with a detectable label.

USE - (I) is useful for producing a polypeptide of interest by culturing (I) under conditions permitting expression of the protein or polypeptide, and recovering the subsequently produced polypeptide of interest. The conditions further permit secretion of the protein or polypeptide of interest. (III) is useful for producing a polypeptide of interest by culturing (III) under conditions permitting expression of the protein or polypeptide and recovering the subsequently produced polypeptide of interest. The protein or polypeptide is expressed as a precursor protein, and further involves cleavage of the precursor into the polypeptide or precursor of interest. The cleavage step is cleavage with an enzyme chosen from Kex-2 like proteases, basic amino acid paired proteases, or Kex-2. The cultivation occurs at pH in the range 6-9, and/or at a temperature between 25-43degreesC. (P1), (P3), (P5), or (P6) is useful for hydrolyzing beta-glucosidic bonds by contacting a beta-glucoside with (P1), (P3), (P5), or (P6). (P2) is useful for hydrolyzing beta-xylosidic bonds by contacting a beta-xyloside with (P2). (V), (VI) or (VII) is useful for producing a polypeptide (claimed).

EXAMPLE - C1 strains NG7C-19 and UV18-25 of *Chrysosporium lucknowense* were transformed with plasmid pUT7201. The vector had a fungal expression cassette, which had *Aspergillus nidulans* glyceraldehyde-3-phosphate dehydrogenase (*gpdA*) promoter2, a synthetic *Trichoderma reesei* cellobiohydrolase1 (*cbh1*) signal *****sequence***** (1,3), *Streptoalloteichus hindustanus* phleomycin-resistance *****gene***** Sh ble4, *A. nidulans* tryptophan-synthase (*trpC*) terminator5. The vector also carried the beta-lactamase *****gene***** (*bla*) and *Escherichia coli* replication origin from plasmid pUC186. C1 protoplasts were transformed according to Durand et al. Primary transformants were toothpicked to glutamine synthetase (GS)+phleomycin plates and grown for 5 days at 32degreesC for resistance verification. Each validated resistant clone was subcloned onto GS plates. Two-subclones per transformant were used to inoculate PDA plates in order to get spores for liquid culture

initiation. The liquid cultures in ICI were grown 5 days at 27degreesC. Then, the cultures were centrifuged and 500 microl of supernatant were collected. From the samples, the proteins were precipitated with TCA and resuspended in Western Sample Buffer to 4 mg/ml of total proteins. Ten microl were loaded on a 12% acrylamide/sodium dodecyl sulfate (SDS) gel and run. Western blotting was conducted using rabbit anti-Sh ble antiserum as primary antibody. The results showed that the heterologous transcription/translation signals from pUT720 were functional in Chrysosporium, and the secretion of human lysozyme was also confirmed. (70 pages)

L8 ANSWER 5 OF 6 FSTA COPYRIGHT 2006 IFIS on STN
 ACCESSION NUMBER: 2002:B1506 FSTA <<LOGINID::20060918>>
 TITLE: Cloning and structural analysis of bgIM gene coding
 for the fungal cell wall-lytic .beta.-1,3-glucan-
 hydrolase BgIM of Bacillus circulans IAM1165.
 AUTHOR: Asano, T.; Taki, J.; Yamamoto, M.; Aono, R.
 CORPORATE SOURCE: Correspondence (Reprint) address, R. Aono, Dep. of
 Biol. Information, Graduate Sch. of Biosci. &
 Biotech., Tokyo Inst. of Tech., Nagatsuta 4259,
 Midori-ku, Yokohama 226-8501, Japan. Fax 81 45 924
 5819. E-mail raono(a)bio.titech.ac.jp
 SOURCE: Bioscience, Biotechnology, and Biochemistry, (2002) 66
 (6) 1246-1255, 28 ref.
 ISSN: 0916-8451
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Bacillus circulans IAM1165 produces multiple isoforms of .beta.-1,3-glucan
 hydrolases. Of these the 42 kDa endo-1,3(4)-.beta.-glucanase (EC 3.2.1.6)
 BgIM is the most active toward Aspergillus oryzae cell walls. A
 gene coding for a BgIM precursor, consisting of 411 amino acid
 residues was cloned and sequenced. The native and recombinant enzyme
 (expressed in Escherichia coli) and a recombinant deletion ***mutant***
 were characterized. The 27 N-terminal amino acid ***sequence*** of
 the precursor was shown to be a signal peptide. The 141 C-terminal amino
 acid ***sequence*** contained family 13 ***carbohydrate*** -binding
 which bound to pachyman, lichenan and A. oryzae cell walls. The central
 domain showed a bacterial .beta.-1,3-glucan hydrolase motif belonging to
 glycosyl ***hydrolase*** family 14. By removal of the
 C-terminal domain B. circulans IAM1165 ***processed*** mature BgIM to
 several 27 kDa fragments that hydrolysed a soluble .beta.-1,3-glucan.

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:634531 CAPLUS <<LOGINID::20060918>>
 DOCUMENT NUMBER: 136:258038
 TITLE: Analysis of the chromosome sequence of the legume
 symbiont Sinorhizobium meliloti strain 1021
 AUTHOR(S): Capela, Delphine; Barloy-Hubler, Frederique; Gouzy,
 Jerome; Bothe, Gordana; Ampe, Frederic; Batut,
 Jacques; Boistard, Pierre; Becker, Anke; Boutry, Marc;
 Cadieu, Edouard; Dreano, Stephane; Gloux, Stephanie;
 Godrie, Therese; Goffeau, Andre; Kahn, Daniel; Kiss,
 Erno; Lelaure, Valerie; Masuy, David; Pohl, Thomas;
 Portetelle, Daniel; Puhler, Alfred; Purnelle,
 Benedicte; Ramsperger, Ulf; Renard, Clotilde;
 Thebault, Patricia; Vandenbol, Micheline; Weidner,
 Stefan; Galibert, Francis
 CORPORATE SOURCE: Laboratoire de Biologie Moleculaire des Relations
 Plantes-Microorganismes, Unite Mixte de Recherche
 (UMR) 215 Centre National de la Recherche Scientifique
 (CNRS), Institut National de la Recherche Agronomique,
 Chemin, Tolosan, F-31326, Fr.
 SOURCE: Proceedings of the National Academy of Sciences of the
 United States of America (2001), 98(17), 9877-9882
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Sinorhizobium meliloti is an .alpha.-proteobacterium that forms
 agronomically important N2-fixing root nodules in legumes. We report here

the complete sequence of the largest constituent of its genome, a 62.7% GC-rich 3654,135-bp circular chromosome. Annotation allowed assignment of a function to 59% of the 3341 predicted protein-coding ORFs, the rest exhibiting partial, weak, or no similarity with any known sequence. Unexpectedly, the level of reiteration within this replicon is low, with only two genes duplicated with more than 90% nucleotide sequence identity, transposon elements accounting for 2.2% of the sequence, and a few hundred short repeated palindromic motifs (RIME1, RIME2, and C) widespread over the chromosome. Three regions with a significantly lower GC content are most likely of external origin. Detailed annotation revealed that this replicon contains all housekeeping genes except two essential genes that are located on pSymB. Amino acid/peptide transport and degrdn. and sugar metab. appear as two major features of the *S. meliloti* chromosome. The presence in this replicon of a large no. of nucleotide cyclases with a peculiar structure, as well as of genes homologous to virulence determinants of animal and plant pathogens, opens perspectives in the study of this bacterium both as a free-living soil microorganism and as a plant symbiont.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:25:46 ON 18 SEP 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:26:20 ON 18 SEP 2006

L2 QUE (GLYCOSYL (W) HYDROLASE)

FILE 'CAPLUS, BIOSIS, SCISEARCH, ESBIODBASE, MEDLINE, USPATFULL, LIFESCI, EMBASE, BIOTECHNO, PASCAL, BIOTECHDS, FSTA' ENTERED AT 12:28:30 ON 18 SEP 2006

L3 3216 S L2
 L4 1563 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE)(S)L3
 L5 105 S (MUTANT OR VARIANT OR MODIF?)(S) L4
 L6 38 S (PROCESS? OR DEGRAD? OR SYNTHES?)(S)L5
 L7 6 S CARBOHYDRAT? (S)L6
 L8 6 DUP REM L7 (0 DUPLICATES REMOVED)

=> log y